Clinical experience with Fluosol-DA (20%) in the United States.
D000208:Acute Disease; D000740:Anemia / Q000188:drug therapy; D000818:Animals; D001802:Blood Substitutes / Q000009:adverse effects / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005466:Fluorocarbons / Q000009:adverse effects / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D010100:Oxygen / Q000097:blood; D014481:United States; D014486:United States Food and Drug Administration
D001802:Blood Substitutes; D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D010100:Oxygen